Advertisement
Advertisement
RCKT
Rocket Pharmaceuticals, Inc. Common Stock
2.44
USDSponsored
-0.10
-3.94%
Oct 30, 15:00 UTC -5
Closed
After-Market
2.43
-0.01
-0.37%
Rocket Pharmaceuticals, Inc. Common Stock (RCKT) Earnings
RCKT Earnings Reports
Positive Surprise Ratio
RCKT beat 25 of 41 last estimates.
61%
Next Report
In 4 Days
Date of Next Report
Nov 05, 2026
Estimate for Q3 26 (Revenue/ EPS)
$459.00K
/-$0.41
Implied change from Q2 26 (Revenue/ EPS)
--
/-14.58%
Implied change from Q3 25 (Revenue/ EPS)
--
/-8.89%
Rocket Pharmaceuticals, Inc. Common Stock earnings per share and revenue
On Aug 10, 2026, RCKT reported earnings of -0.48 USD per share (EPS) for Q2 26, missing the estimate of 0.24 USD, resulting in a -294.57% surprise. Revenue reached --, compared to an expected 20.40 million, with a -100.00% difference. The market reacted with a -3.85% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 10 analysts forecast an EPS of -0.41 USD, with revenue projected to reach 459.00 thousand USD, implying an decrease of -14.58% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
NovoCure Limited Ordinary Shares
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.24
Actual
-$0.09
Surprise
+63.88%
Phathom Pharmaceuticals, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$0.14
Actual
$0.04
Surprise
+128.27%
AstraZeneca PLC
Report Date
Oct 30, 2026 For Q3 26
Estimate
$2.66
Actual
$2.79
Surprise
+4.56%
Gilead Sciences Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$2.24
Actual
$2.54
Surprise
+13.66%
Bristol-Myers Squibb Co.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.20
Actual
$1.35
Surprise
+11.66%
Regeneron Pharmaceuticals Inc
Report Date
Oct 30, 2026 For Q3 26
Estimate
$16.47
Actual
$20.07
Surprise
+21.79%
Illumina Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.38
Actual
$1.44
Surprise
+4.18%
Alnylam Pharmaceuticals, Inc.
Report Date
Oct 29, 2026 For Q3 26
Estimate
$1.65
Actual
$16.26
Surprise
+885.34%
Exelixis Inc
Report Date
Oct 29, 2026 For Q3 26
Estimate
$0.81
Actual
$0.94
Surprise
+15.64%
Kymera Therapeutics, Inc. Common Stock
Report Date
Oct 29, 2026 For Q3 26
Estimate
-$1.29
Actual
-$1.32
Surprise
-2.17%
FAQ
What were Rocket Pharmaceuticals, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Rocket Pharmaceuticals, Inc. Common Stock reported EPS of -$0.48, missing estimates by -294.57%, and revenue of $0.00, -100% below expectations.
How did the market react to Rocket Pharmaceuticals, Inc. Common Stock's Q2 2026 earnings?
The stock price moved down -3.85%, changed from $3.64 before the earnings release to $3.50 the day after.
When is Rocket Pharmaceuticals, Inc. Common Stock expected to report next?
The next earning report is scheduled for Nov 05, 2026.
What are the forecasts for Rocket Pharmaceuticals, Inc. Common Stock's next earnings report?
Based on 10
analysts, Rocket Pharmaceuticals, Inc. Common Stock is expected to report EPS of -$0.41 and revenue of $459.00K for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.